Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01119833 · ClinicalTrials.gov registry record · Phase 2
Study of GMI-1070 for the Treatment of Sickle Cell Pain Crisis
A Phase 2 study, sponsored by GlycoMimetics Incorporated.
- Completed
- Registry status
- Phase 2
- Development phase
- 81
- Enrollment target
NCT01119833: Completed Phase 2 study, sponsored by GlycoMimetics Incorporated.
NCT01119833 is a Phase 2 study that has completed, run by GlycoMimetics Incorporated. The registered enrollment target is 81 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01119833, a Phase 2 study, has completed, sponsored by GlycoMimetics Incorporated.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 81 participants
- Enrollment target
Study Summary
GMI-1070 is a new drug that may reduce the stickiness of cells in the blood. The purpose of this study is to evaluate whether GMI-1070 can reduce the time it takes for pain to go away in patients with vaso-occlusive crisis (also known as a sickle cell pain crisis). The study will also collect information on the safety of GMI-1070, how much of the drug is in the blood and urine, and if there are any other effects when used in patients who are in the hospital for a sickle cell pain crisis.
Interventions
- DRUG Placebo
- DRUG GMI-1070
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 2010-05 |
| Est. Completion | 2013-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01119833
The ClinicalTrials.gov registry entry for NCT01119833 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 81 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlycoMimetics Incorporated, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01119833 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01119833 about?
NCT01119833 is a clinical study titled "Study of GMI-1070 for the Treatment of Sickle Cell Pain Crisis". GMI-1070 is a new drug that may reduce the stickiness of cells in the blood. The purpose of this study is to evaluate whether GMI-1070 can reduce the time it takes for pain to go away in patients with vaso-occlusive crisis (also known as a sickle cell pain crisis). The study will also collect inform...
What is the current status of trial NCT01119833?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 81 participants. The study started on 2010-05. Estimated completion is 2013-12.
What interventions are being tested in trial NCT01119833?
The interventions under investigation include: Placebo (DRUG), GMI-1070 (DRUG).
Who is sponsoring clinical trial NCT01119833?
This trial is sponsored by GlycoMimetics Incorporated, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.